These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 31865731)

  • 21. Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study.
    Ni W; Chen J; Xiao Z; Yu S; Zhang W; Zhou Z; Chen D; Feng Q; Chen X; Lin Y; Zhu K; Gao S; Xue Q; Mao Y; Cheng G; Sun K; Liu X; Fang D
    Thorac Cancer; 2019 Jun; 10(6):1431-1440. PubMed ID: 31102336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
    Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
    Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
    Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ
    Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant Chemotherapy and Dose Escalation in Definitive Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.
    Koh HK; Park Y; Koo T; Park HJ; Lee MY; Chang AR; Hong S; Bae H
    Anticancer Res; 2020 Mar; 40(3):1771-1778. PubMed ID: 32132086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study.
    Saito Y; Hamamoto Y; Hirata K; Yamasaki M; Watanabe M; Abe T; Tsubosa Y; Hamai Y; Murakami K; Bamba T; Yoshii T; Tsuda M; Watanabe M; Ueno M; Kitagawa Y
    BMC Cancer; 2023 Mar; 23(1):283. PubMed ID: 36978040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival risk prediction model for patients with pT
    Qi Z; Hu Y; Qiu R; Li J; Li Y; He M; Wang Y
    J Cardiothorac Surg; 2021 May; 16(1):121. PubMed ID: 33933129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [IMRT-based preoperative neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma (ESCC): an analysis of outcome and prognosis].
    Men Y; Hui ZG; Liang J; Feng QF; Chen DF; Zhang HX; Xiao ZF; Zhou ZM; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):682-6. PubMed ID: 27647401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative Radiotherapy in Curatively Resected Esophageal Squamous Cell Carcinoma With Occult Recurrent Laryngeal Nerve Lymph Node Metastasis.
    Liu D; Wu S; Ni J; Xiang J; Zhang J
    Cancer Control; 2024; 31():10732748241285142. PubMed ID: 39259654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
    Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postoperative Adjuvant Therapy for Patients with pN+ Esophageal Squamous Cell Carcinoma.
    Li J; Qiu R; Hu Y; Wang Y; Qi Z; He M; Li Y
    Biomed Res Int; 2021; 2021():8571438. PubMed ID: 33553432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery.
    Pao TH; Chen YY; Chang WL; Wu SY; Lai WW; Tseng YL; Chung TJ; Lin FC
    PLoS One; 2024; 19(3):e0300173. PubMed ID: 38547184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].
    Wang XM; Wang L; Wang X; Chen JQ; Li C; Zhang WC; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Han C; Pang QS; Wang P; Sun XC; Zhang KX; Li GF; Li L; Liu ML; Wang YD; Qiao XY; Zhu SC; Zhou ZM; Zhao YD; Xiao ZF
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):889-896. PubMed ID: 34407597
    [No Abstract]   [Full Text] [Related]  

  • 37. Lack of any prognostic value of body mass index for patients undergoing chemoradiotherapy for esophageal squamous cell carcinoma.
    Zhang F; Wang CS; Sun B; Tian GB; Cao FL; Cheng YF
    Asian Pac J Cancer Prev; 2014; 15(7):3075-9. PubMed ID: 24815450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endoscopic resection as an independent predictive factor of local control in patients with T1bN0M0 esophageal squamous cell carcinoma treated with chemoradiotherapy: a retrospective study.
    Miyazaki T; Myojin M; Hosokawa M; Aoyama H; Okahara S; Takahashi H
    Radiat Oncol; 2022 Jan; 17(1):11. PubMed ID: 35057830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemoradiotherapy for patients with pathologic node-positive esophageal cancer following radical resection is associated with improved survival.
    Zheng B; Chen M; Chen C; Xiao J; Cai B; Zhang S; Liang M; Zeng T; Chen H; Wu W; Xu G; Zheng W; Zhu Y; Chen C
    Ann Transl Med; 2020 Dec; 8(24):1633. PubMed ID: 33490145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors of radiotherapy in patients with node-positive thoracic esophageal squamous cell carcinoma after radical surgery.
    Lu JC; Tao H; Chen ZZ; Qian PD
    Dis Esophagus; 2009; 22(6):490-5. PubMed ID: 19191849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.